Showing 3161-3170 of 6035 results for "".
- AbbVie to Buy Allergan in Deal Worth $63 Billionhttps://modernod.com/news/abbvie-to-buy-allergan-in-deal-worth-63-billion/2476686/A blockbuster merger of two large pharma companies will have an impact on the eye care market as AbbVie announced its plans to buy Allergan in a deal worth $63 billion. Under the agreed terms, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share they h
- Avellino Labs Founder Gene Lee Receives 2019 Ellis Island Medal of Honorhttps://modernod.com/news/avellino-labs-founder-gene-lee-receives-2019-ellis-island-medal-of-honor/2476683/Avellino Labs announced the company’s founder, chairman, and president, Gene Lee, is a recipient of a 2019 Ellis Island Medal of Honor. In addition, Mr. Lee has been appointed to the World Economic Forum’s Precision Medicine Council. One of the nation’s most prestigious awards, the Ellis I
- Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Deliveryhttps://modernod.com/news/alnylam-announces-progress-with-rnai-therapeutics-platform-including-oral-route-of-administration-and-cns-and-ocular-delivery/2476682/Alnylam Pharmaceuticals announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target. Oral delivery could broaden the clinical
- Ocular Therapeutix Receives FDA Approval of Supplemental NDA for Dextenza for Postoperative Ocular Inflammationhttps://modernod.com/news/ocular-therapeutix-receives-fda-approval-of-supplemental-nda-for-dextenza-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery/2476680/Ocular Therapeutix announced the FDA approved a supplemental new drug application (NDA) for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication. With the approval of the supplemental NDA, Dextenza is now approved for the treatment of b
- Carl Zeiss Meditec Announces Investment in Early Stage MIGS Device Maker MicroOptxhttps://modernod.com/news/carl-zeiss-meditec-announces-investment-in-clinical-stage-migs-device-maker-microoptx/2476679/Carl Zeiss Meditec announced that it has become a shareholder of MicroOptx, a privately held company focused on minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical tec
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- Alcon Showcases News Contact Lens Innovations and the iLUX System at the 2019 Optometry’s Meetinghttps://modernod.com/news/alcon-showcases-news-contact-lens-innovations-and-the-ilux-system-at-the-2019-optometrys-meeting/2476673/Alcon will launch Dailies Colors contact lenses at the 2019 Optometry’s Meeting, as well as give attendees a preview of PRECISION1 contact lenses coming soon to the US. These innovations, together with updates on the iLUX MGD Treatment System, new clinical data and practice insights, will be feat
- The Vision Council Files Joint Letter in Opposition of China 301 Tariffs, Will Testify on Thursdayhttps://modernod.com/news/the-vision-council-files-joint-letter-in-opposition-of-china-301-tariffs-will-testify-on-thursday/2476669/This weekend, The Vision Council, the American Academy of Ophthalmology, National Association of Opticians and Optometrists, Opticians Association of America, National Association of Vision Care Plans, Prevent Blindness, and OneSight jointly filed a letter to the United States Trade Representativ
- New Survey Highlights Growing Insurance Problem That Delays Sight-Saving Carehttps://modernod.com/news/new-survey-highlights-growing-insurance-problem-that-delays-sight-saving-care/2476670/The majority of ophthalmologists in a new survey said that a cost-management tool required by health insurance companies is delaying or disrupting the sight-saving care they give their patients. The tool is called prior authorization. Insurance companies use it to control costs by reducing medica
- House Subcommittee Urges FTC to Modernize Contact Lens Verification Processhttps://modernod.com/news/house-subcommittee-urges-ftc-to-modernize-contact-lens-verification-process/2476657/The Health Care Alliance for Patient Safety expressed its support of the House Committee on Appropriations for urging the Federal Trade Commission (FTC) to update the process by which contact lens prescriptions are verified, according to a news